Climb Bio

Advertisement

cGxPJobs Banner

Climb Bio Phase 1 Data Support CLYM116 Q12W Dosing in IgA Nephropathy

Wellesley Hills, Mass., September 3, 2026 Climb Bio announced positive initial Phase 1 clinical data for CLYM116, its investigational...

By cGxPwire Editor
September 4, 2026

Read More

Climb Bio Advances CLYM116 After Encouraging Phase 1 Safety Results

WELLESLEY HILLS, Mass., June 5, 2026 Climb Bio, Inc. announced the presentation of initial Phase 1 safety data and...

By cGxPwire Editor
June 6, 2026

Read More

Advertisement

cGxPJobs

Directory